Merck to buy Elanco's aqua health business for $1.3 bln

The deal, expected to be completed mid-year, will help Merck gain access to DNA-based vaccine Clynav, which protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment.